维甲酸治疗骨髓增生异常综合征影响疗效的因素

All Trans-retinoic Acids in the Treatment of Myelodysplastic Syndrome—An Analysis of Factors Relevant to the Therapeutic Effects

全反式维甲酸治疗50例MDS、其中RA型26/50(52%),RSA 3/50(6%)、RAEB16/50(32%)、RAEB/T 5/50(10%)。用法:维甲酸30～90mg/d,分次口服,个别100mg/d。总有效率为58%,其中8/50(16%)获缓解。影响疗效因素分析结果示:1.亚型与疗效有关。以RA型较好:2.患者GM-CFU受抑较轻者其疗效较受抑重者为好;3.副反应一般较轻不影响治疗进行。

Fifty patients with myelodysplastic syndrome (MDS) were treated with alltreansretinoic acid. Among them 26 (52%) belonged to subtype RA, 3(6%) to RAS, 16(32%) to RAEB, and 5(10%) to RAER/T. The total response rate was 58%, 8 patients (16%) achieved satisfactory am-fission. Analysis of factors rdevant to the effect of the treatment showed that the subtyping and GM-CFU status played major roles. The subtype RA had a better effect. Patients with higher GM-CFU responsed better than those with a lower one Side effects were relatively mild and usually did not necessitate the discontinuation of the treatment.